Anti-Granzyme B Monoclonal Antibody (Clone 2F5F2D10)

Granzyme B is a serine protease that is involved in cytotoxic T lymphocyte- and natural killer cell-induced cell death. It localizes to cytoplasmic granules prior to release into the immunological synapse formed with a target cell. Granzyme B cleaves its substrates after an aspartate residue and targets caspase-3, caspase-8, and gasdermin E (GSDME), among others. It is involved in caspase-dependent and -independent apoptosis, necrosis, DNA fragmentation, pyroptosis, viral infection, and antitumor immunity. Knockout of the gene encoding granzyme B, GZMB, reduces disease severity in a mouse model of epidermolysis bullosa acquisita, an autoimmune disease characterized by blistering of the skin. Serum and synovial levels of granzyme B are elevated in patients with rheumatoid arthritis. Cayman's Granzyme B Monoclonal Antibody (Clone 2F5F2D10) can be used for ELISA and immunohistochemistry (IHC) applications.Synonyms: CTLA-1, Cytotoxic Serine Protease B, Cytotoxic T-lymphocyte Proteinase 2, Fragmentin-2, Granzyme-2, GrB. Immunogen: Recombinant human granzyme B. Clone Designation: 2F5F2D10. Formulation: (Request formulation change), 50, 100, or 200 µl of protein A-affinity purified monoclonal antibody. Storage Buffer: 0.2 µm filtered solution in PBS. Host: Mouse. Applications: ELISA, IHC.